| Recruiting | Pre-malignant States to Hematologic Malignancies in Firefighters NCT06870760 | Wake Forest University Health Sciences | — |
| Not Yet Recruiting | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT NCT07254793 | University of Arizona | Phase 1 |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Recruiting | GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL NCT06875063 | The First Affiliated Hospital of Xiamen University | Phase 1 |
| Not Yet Recruiting | A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy NCT07249528 | Memorial Sloan Kettering Cancer Center | N/A |
| Not Yet Recruiting | Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study NCT07292272 | University of Nebraska | Phase 2 |
| Recruiting | PIC1 Injection Therapy for Relapsed/Refractory B-NHL NCT07456371 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas NCT07222631 | University of California, San Diego | Phase 1 / Phase 2 |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Recruiting | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies NCT07284927 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Amping up With PemJAK NCT07283822 | Seda S. Tolu | Phase 2 |
| Not Yet Recruiting | Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Rec NCT05416554 | Stanford University | N/A |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690 | Baylor College of Medicine | Phase 1 |
| Recruiting | Mozobil for Autologous Hematopoietic Stem Cell Transplantation NCT07188090 | Thomas Jefferson University | Phase 2 |
| Withdrawn | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphom NCT06005649 | Juventas Cell Therapy Ltd. | Phase 1 / Phase 2 |
| Recruiting | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07260812 | TCRx Therapeutics Co.Ltd | Phase 1 |
| Recruiting | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin NCT06383338 | Murdoch Childrens Research Institute | Phase 1 |
| Withdrawn | Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen NCT06767956 | University of Pittsburgh | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety and Clinical Efficacy of STR-P004 NCT07003178 | Starna Therapeutics | EARLY_Phase 1 |
| Recruiting | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematolog NCT07016165 | Gadjah Mada University | Phase 4 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Smal NCT06876662 | Eli Lilly and Company | Phase 4 |
| Recruiting | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib NCT06876649 | Eli Lilly and Company | Phase 4 |
| Active Not Recruiting | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or NCT06939283 | Werewolf Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL NCT06768905 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Terminated | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed o NCT05994157 | Y-mAbs Therapeutics | Phase 1 |
| Recruiting | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma NCT06915246 | VIVUS LLC | Phase 2 |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology C NCT06418204 | Wake Forest University Health Sciences | — |
| Recruiting | Epco, Zanu, Ritux for R/R FL or MZL NCT06563596 | Reid Merryman, MD | Phase 2 |
| Recruiting | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab NCT06447376 | Taylor Brooks | Phase 1 |
| Recruiting | Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL NCT07195799 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/ref NCT06720701 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT06622226 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy NCT06522932 | Michael Randall | Phase 1 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Terminated | Impact of Respiratory Training in Lymphoma Survivors NCT05938127 | University of Colorado, Denver | N/A |
| Recruiting | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. NCT06484985 | Axter Therapeutics (Beijing) Co., Ltd | Phase 1 |
| Recruiting | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL NCT05583071 | University of Cologne | Phase 2 |
| Recruiting | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma NCT06479356 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Recruiting | PTCy and ATG for MSD and MUD Transplants NCT06299462 | Instituto Nacional de Cancer, Brazil | Phase 1 / Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU NCT06116110 | Miltenyi Biomedicine GmbH | — |
| Recruiting | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Re NCT06393335 | The Children's Hospital of Zhejiang University School of Medicine | EARLY_Phase 1 |
| Recruiting | Vitamin A and D Supplementation in Allogeneic HCT NCT06508099 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) NCT06004011 | Implenomics | N/A |
| Recruiting | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymp NCT06323525 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies NCT06206174 | Shenzhen TargetRx Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma NCT06088654 | Innate Pharma | Phase 1 / Phase 2 |
| Recruiting | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma NCT05998642 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients NCT05921812 | Sohag University | — |
| Completed | The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients NCT05443165 | Akdeniz University | N/A |
| Recruiting | A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas NCT06219356 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. NCT06424379 | Hospices Civils de Lyon | — |
| Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma NCT06180174 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | Safety and Efficacy Evaluation of Next-generation CD19-UCART NCT05381181 | Bioray Laboratories | Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | TmCD19-IL18 in CD19+ Cancers NCT05989204 | University of Pennsylvania | Phase 1 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors NCT06002828 | ECOG-ACRIN Cancer Research Group | — |
| Recruiting | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufacture NCT06357754 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Terminated | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma NCT06018129 | Genmab | Phase 1 / Phase 2 |
| Not Yet Recruiting | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomar NCT05834426 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Recruiting | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018 | CytoCares Inc | Phase 1 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Completed | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multi NCT05896774 | Pfizer | Phase 1 |
| Recruiting | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas NCT05389423 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | The Pathogenesis and Prognostic Factors of Lymphoma NCT06203652 | Shanghai Zhongshan Hospital | — |
| Recruiting | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory NCT05794958 | Stanford University | Phase 1 |
| Recruiting | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma NCT05826535 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) NCT05878184 | Sana Biotechnology | Phase 1 |
| Not Yet Recruiting | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation NCT03969693 | Chang Gung Memorial Hospital | — |
| Recruiting | Lifestyle Intervention of Food and Exercise for Lymphoma Survivors NCT05839210 | University of Miami | N/A |
| Active Not Recruiting | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas NCT05400109 | David Wald | Phase 1 |
| Active Not Recruiting | A Rollover Study of CC-122 NCT05688475 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Completed | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies NCT05371054 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma NCT05346809 | Divaya Bhutani | Phase 2 |
| Terminated | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) NCT05721222 | Genmab | Phase 1 / Phase 2 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Improving Exercise Capacity With a Tailored Physical Activity Intervention NCT05595577 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL NCT05627856 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Re NCT06277011 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Completed | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive N NCT05665725 | Timothy Voorhees | Phase 1 |
| Recruiting | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients NCT05529069 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Recruiting | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897 | Marker Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+ NCT05645107 | Grifols Therapeutics LLC | Phase 3 |
| Terminated | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Ly NCT05664217 | Nektar Therapeutics | Phase 2 / Phase 3 |
| Completed | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma NCT05678998 | Werewolf Therapeutics, Inc. | Phase 1 |
| Terminated | First in Human, Dose Escalation, Dose Expansion Study of AUR105 NCT05605119 | Aurigene Discovery Technologies Limited | Phase 1 |
| Terminated | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT05611853 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination Wi NCT05169515 | Hoffmann-La Roche | Phase 1 |
| Terminated | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers NCT04083170 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma NCT05574114 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between th NCT05206357 | Genmab | Phase 1 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas NCT05415098 | Ascentage Pharma Group Inc. | Phase 1 |
| Terminated | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics NCT05607199 | Aurigene Discovery Technologies Limited | Phase 1 |
| Completed | Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial NCT05205512 | City of Hope Medical Center | N/A |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Active Not Recruiting | Study of 3D189 in Patients With Hematologic Malignancies NCT05320809 | 3D Medicines | Phase 1 |
| Terminated | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin NCT05205161 | AstraZeneca | Phase 1 |
| Terminated | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refracto NCT05296525 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Withdrawn | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CA NCT05037669 | University of Pennsylvania | Phase 1 |
| Active Not Recruiting | RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherap NCT04827862 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combinat NCT05283720 | Genmab | Phase 2 |
| Completed | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL NCT05233033 | Kymera Therapeutics, Inc. | Phase 1 |
| Unknown | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantat NCT05005299 | Melbourne Health | Phase 1 |
| Withdrawn | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) NCT03768310 | Baylor College of Medicine | Phase 1 |
| Unknown | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies NCT05410041 | Beijing Boren Hospital | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tum NCT05528055 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | GVM±R in Patients With Relapsed or Refractory Aggressive NHL NCT05299164 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P NCT05294731 | BeiGene | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Ri NCT05171647 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-deliver NCT05106192 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malign NCT04684979 | Baptist Health South Florida | Phase 2 |
| Completed | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-C NCT05169658 | University of Washington | Phase 2 |
| Recruiting | Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families NCT05425992 | University of Colorado, Denver | — |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Recruiting | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively NCT05840575 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy NCT05044039 | Washington University School of Medicine | Phase 1 |
| Terminated | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplant NCT05181540 | Angiocrine Bioscience | Phase 3 |
| Withdrawn | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiova NCT05169151 | M.D. Anderson Cancer Center | — |
| Completed | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignan NCT05269940 | Nanjing Zenshine Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma NCT05253495 | New York Medical College | Phase 2 |
| Active Not Recruiting | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants Wit NCT05207670 | Genentech, Inc. | Phase 2 |
| Unknown | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-ce NCT05200312 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | A Study of BTX-1188 in Subjects With Advanced Malignancies NCT05144334 | Biotheryx, Inc. | Phase 1 |
| Recruiting | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients NCT05098613 | University of Colorado, Denver | Phase 1 |
| Unknown | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma NCT05021770 | Huiqiang Huang | Phase 1 / Phase 2 |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Completed | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy NCT05065866 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Terminated | A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma NCT05127811 | Zentera Therapeutics HK Limited | Phase 1 |
| Recruiting | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET NCT05093335 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma NCT05019976 | University of Chicago | N/A |
| Terminated | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refra NCT04809467 | Incyte Corporation | Phase 1 / Phase 2 |
| Unknown | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT NCT05066958 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Unknown | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non- NCT05420493 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Completed | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study NCT05053100 | Mayo Clinic | — |
| Terminated | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) NCT04745832 | MEI Pharma, Inc. | Phase 3 |
| Completed | Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events NCT05123001 | Stanford University | — |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Rel NCT04739813 | National Cancer Institute (NCI) | Phase 1 |
| Completed | IIT2020-20-SHIRAZIP-WALK: Nature Walks NCT04896580 | Cedars-Sinai Medical Center | N/A |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Terminated | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin L NCT04161118 | University of Cologne | Phase 2 |
| Active Not Recruiting | huCART19-IL18 in CD19+ Cancers NCT04684563 | University of Pennsylvania | Phase 1 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Active Not Recruiting | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies NCT04732845 | Benjamin Tomlinson | Phase 1 |
| Terminated | Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma NCT05221385 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depl NCT04099966 | Mitchell Cairo | Phase 2 |
| Completed | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma NCT04673617 | Artiva Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Ly NCT04775680 | Adagene (Suzhou) Limited | Phase 1 / Phase 2 |
| Terminated | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphom NCT04419389 | Aprea Therapeutics | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Terminated | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced NCT04504708 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High NCT04718675 | Kronos Bio | Phase 1 / Phase 2 |
| Unknown | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal NCT04758650 | Universitair Ziekenhuis Brussel | Phase 2 |
| Terminated | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers NCT04072393 | Washington University School of Medicine | N/A |
| Terminated | Heart Rate Variability, Vagus Nerve and Cancer NCT04718610 | Centre Hospitalier Henri Duffaut - Avignon | N/A |
| Withdrawn | Diet, Physical Activity and Body Composition Changes During R-CHOP NCT04293900 | George Washington University | — |
| Completed | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Ma NCT04689204 | He Huang | EARLY_Phase 1 |
| Active Not Recruiting | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in NCT04671693 | Centre Leon Berard | N/A |
| Completed | 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL NCT04601831 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study NCT04537871 | City of Hope Medical Center | — |
| Terminated | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Rela NCT04502706 | Gilead Sciences | Phase 1 |
| Active Not Recruiting | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia NCT04606433 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Terminated | The clonoSEQ® Watch Registry NCT04545333 | Adaptive Biotechnologies | — |
| Completed | Phase 1 First in Human Study of ZN-d5 as a Single Agent NCT04500587 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma NCT04514393 | Huiqiang Huang | Phase 2 |
| Completed | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity NCT04150913 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Completed | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors NCT03935282 | Wake Forest University Health Sciences | N/A |
| Completed | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies NCT04543305 | Prelude Therapeutics | Phase 1 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Terminated | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, NCT04553692 | IGM Biosciences, Inc. | Phase 1 |
| Completed | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL NCT04555811 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Terminated | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma NCT04217317 | Wake Forest University Health Sciences | Phase 2 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Completed | Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relaps NCT04240808 | University of Colorado, Denver | Phase 1 |
| Completed | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transp NCT04478123 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma NCT04434833 | Ruijin Hospital | — |
| Active Not Recruiting | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma NCT04459416 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Unknown | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma NCT04356846 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Unknown | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor NCT04337606 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Healt NCT04000880 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma NCT07041827 | The Netherlands Cancer Institute | — |
| Recruiting | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With NCT05950165 | Cho Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Mal NCT04227015 | He Huang | EARLY_Phase 1 |
| Active Not Recruiting | A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients NCT04024696 | Xynomic Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI NCT04154228 | Tel-Aviv Sourasky Medical Center | N/A |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Unknown | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma NCT04169932 | Shanghai Longyao Biotechnology Inc., Ltd. | EARLY_Phase 1 |
| Terminated | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. NCT03886649 | Swiss Cancer Institute | Phase 1 |
| Unknown | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL NCT04206943 | Acibadem University | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NCT04136756 | Nektar Therapeutics | Phase 1 |
| Terminated | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma NCT04082936 | IGM Biosciences, Inc. | Phase 1 / Phase 2 |
| Terminated | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With NCT03779113 | Hutchmed | Phase 1 |
| Completed | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cel NCT03755414 | Washington University School of Medicine | Phase 1 |
| Recruiting | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 | CellCentric Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Ac NCT04045028 | Genentech, Inc. | Phase 1 |
| Terminated | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CAR NCT04035434 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Terminated | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or Mor NCT03768505 | MEI Pharma, Inc. | Phase 2 |
| Completed | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) NCT03904134 | Center for International Blood and Marrow Transplant Research | N/A |
| Active Not Recruiting | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies NCT03913949 | Ascentage Pharma Group Inc. | Phase 1 |
| Unknown | CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma NCT04237428 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | N/A |
| Completed | Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx NCT03923504 | Virginia Commonwealth University | N/A |
| Completed | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma NCT03570892 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation NCT03925935 | Angiocrine Bioscience | Phase 1 |
| Terminated | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalido NCT03645395 | Molecular Templates, Inc. | Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma NCT03713580 | Case Comprehensive Cancer Center | Phase 1 |
| Recruiting | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra NCT03666000 | Imugene Limited | Phase 1 |
| Completed | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies NCT03885947 | Alla Keyzner | Phase 1 |
| Completed | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma NCT03610724 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red NCT03852407 | University of Liege | Phase 2 |
| Unknown | Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy NCT03790891 | Timmune Biotech Inc. | EARLY_Phase 1 |
| Unknown | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma NCT03602131 | Sichuan University | Phase 2 |
| Completed | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma NCT03802955 | Adagene (Suzhou) Limited | Phase 1 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Completed | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Ref NCT03711578 | Rhizen Pharmaceuticals SA | Phase 2 |
| Completed | Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environme NCT03706625 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Unknown | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymp NCT03688451 | Tahir Latif | Phase 2 |
| Completed | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL NCT03806179 | Nordic Nanovector | Phase 1 |
| Terminated | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies NCT03671590 | TG Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged H NCT03620578 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors NCT03615105 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk NCT03573310 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma NCT03434769 | Benjamin Tomlinson | Phase 1 |
| Completed | Patient Preference for Pegfilgrastim (Neulasta®) Application Forms NCT03619993 | iOMEDICO AG | N/A |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Unknown | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients NCT03528421 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Completed | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers NCT03454451 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With NCT03379051 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincri NCT03467373 | Hoffmann-La Roche | Phase 1 |
| Completed | Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma NCT03185325 | Assiut University | — |
| Completed | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT03424603 | Sutro Biopharma, Inc. | Phase 1 |
| Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product NCT03436771 | Juno Therapeutics, a Subsidiary of Celgene | — |
| Completed | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PC NCT03255018 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma NCT03223610 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation NCT03434730 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy NCT03595813 | Institut Paoli-Calmettes | N/A |
| Unknown | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non NCT03355859 | Zhao Weili | Phase 1 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Withdrawn | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) NCT02657447 | Nordic Nanovector | Phase 1 |
| Terminated | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies NCT03422679 | Cellestia Biotech AG | Phase 1 / Phase 2 |
| Withdrawn | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20 NCT03169790 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Unknown | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non NCT03344367 | Peking University | Phase 1 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Completed | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL NCT03019666 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? NCT03265574 | South Tees Hospitals NHS Foundation Trust | Phase 3 |
| Terminated | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma NCT03311126 | University of Wisconsin, Madison | Phase 2 |
| Active Not Recruiting | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers NCT03212404 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Completed | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related NCT03595800 | Institut Paoli-Calmettes | Phase 3 |
| Completed | A Study of PLX2853 in Advanced Malignancies. NCT03297424 | Opna Bio LLC | Phase 1 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving NCT03207256 | TG Therapeutics, Inc. | Phase 2 |
| Terminated | Cyclophosphamide and Alemtuzumab In Lymphoma NCT03132584 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies NCT03056339 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) NCT03571308 | University Hospital Southampton NHS Foundation Trust | Phase 1 / Phase 2 |
| Unknown | Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma NCT03260231 | University of Belgrade | N/A |
| Recruiting | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) NCT02917083 | Baylor College of Medicine | Phase 1 |
| Completed | Identification of Occupational Exposures in Acute Hematologic Malignancy NCT03316209 | Centre Hospitalier Intercommunal Creteil | — |
| Recruiting | Auto Stem Cell Transplant for Lymphoma Patients NCT03125642 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Recruiting | Bergamo Lymphoid Cancer Registry NCT03131531 | A.O. Ospedale Papa Giovanni XXIII | — |
| Terminated | Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide NCT03065790 | Abramson Cancer Center at Penn Medicine | — |
| Terminated | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide NCT03088709 | Loyola University | Phase 2 |
| Completed | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery NCT02955043 | University of Wisconsin, Madison | N/A |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Withdrawn | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant NCT02115126 | David Rizzieri, MD | Phase 2 |
| Terminated | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With NCT02953509 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure NCT03323541 | University Hospital, Brest | — |
| Unknown | Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow NCT02788084 | Alberta Health Services, Calgary | — |
| Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery NCT02767388 | University of Nebraska | — |
| Terminated | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma NCT02811679 | Massachusetts General Hospital | Phase 2 |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Withdrawn | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Smal NCT02640833 | AbbVie | Phase 1 |
| Completed | Auto/Allo Tandem Transplant for Relapsed B-NHL NCT03205657 | New York Medical College | — |
| Completed | Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients NCT03127020 | PIQUR Therapeutics AG | Phase 2 |
| Terminated | Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects NCT02519270 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |